Premium
Possible Roxithromycin‐Induced Fulminant Hepatic Failure in a Child
Author(s) -
EastonCarter Kylie L.,
Hardikar Winita,
Smith Arnold L.
Publication year - 2001
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.21.9.867.34552
Subject(s) - roxithromycin , medicine , fulminant hepatic failure , jaundice , vomiting , anorexia , rash , hepatitis , pediatrics , liver transplantation , maculopapular rash , surgery , antibiotics , transplantation , erythromycin , biology , microbiology and biotechnology
A pediatric formulation of roxithromycin is a relatively new addition to the antibiotic market in Australia. A previously healthy 5‐year‐old boy with no significant medical history was treated with roxithromycin 50 mg twice/day for cough, fever, and anorexia. After completing a 5‐day course of the agent, he developed a nonpruritic, nonurticarial, erythematous, maculopapular, generalized rash and occasional vomiting. Three days later his symptoms included jaundice, dark urine, and pale stools. Laboratory results revealed acute hepatitis, and the patient was admitted to the hospital. His hepatic function continued to deteriorate, so the boy was transferred to a tertiary pediatric hospital. His condition continued to worsen, and 6 days after transfer, he underwent liver transplantation. Clinicians should be aware of potential hepatic complications associated with the use of roxithromycin.